LWMG
ADAP

Levy Wealth Management Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Levy Wealth Management Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,590
Closed -$36K – 70
2022
Q1 		$36K Buy
+17,590
New +$47.5K 0.01% 75

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Levy Wealth Management Group's ADAP Position: Q2 2022 in Review

Levy Wealth Management Group sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 17,590 shares — an estimated $36K sold.

Levy Wealth Management Group first reported a position in ADAP in Q1 2022 and held it in 1 quarter. The position peaked at $36K in Q1 2022. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

  • Levy Wealth Management Group reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Levy Wealth Management Group sold 17,590 Adaptimmune Therapeutics shares in Q2 2022, an estimated $36K.
  • Levy Wealth Management Group first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 1 quarter.
  • Levy Wealth Management Group's Adaptimmune Therapeutics position peaked at $36K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on Levy Wealth Management Group's 13F filing for Q2 2022, filed 27 Jul 2022.